Merck's WINREVAIR shows promise in heart failure trial

March 29, 2026 11:45 AM

Merck (NYSE: MRK) announced that its drug WINREVAIR met the primary endpoint in a Phase 2 trial for treating adults ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found